What are the side effects of baclofen in patients with alcohol use disorders?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Side Effects of Baclofen in Patients with Alcohol Use Disorders

Baclofen, a GABA-B receptor agonist used as a muscle relaxant, has shown benefit in maintaining alcohol abstinence in patients with alcohol use disorders, but comes with several potential side effects that require monitoring.

Common Side Effects

  • Transient drowsiness is the most common side effect, affecting 10-63% of patients taking baclofen 1
  • Disruption of wake-sleep cycle affects approximately 63% of patients and is the most frequently reported group of adverse effects 2
  • Dizziness (5-15%), weakness (5-15%), and fatigue (2-4%) are other common side effects 1
  • Neuropsychiatric effects include confusion (1-11%), headache (4-8%), and insomnia (2-7%) 1

Serious Side Effects

  • Impaired mentation is a significant concern, particularly in patients with advanced liver disease or hepatic encephalopathy 3
  • Hypotension occurs in up to 9% of patients 1
  • Potentially dangerous adverse effects include bouts of somnolence and hypomanic episodes 2
  • Seizures can occur, particularly during withdrawal from baclofen 4
  • Baclofen withdrawal syndrome characterized by confusion, agitation, seizures, and delirium may be mistaken for alcohol withdrawal syndrome 4

Special Considerations for AUD Patients

  • Baclofen is the only AUD pharmacotherapy tested in a randomized controlled trial specifically in patients with alcoholic cirrhosis 3
  • Patients with hepatic encephalopathy were excluded from trials due to baclofen's potential to impair mentation 3
  • Women report significantly more adverse effects than men when taking high-dose baclofen 2
  • Risk of abuse exists due to baclofen's mood-elevating properties, particularly in patients with comorbid depression 5

Dosing and Toxicity Considerations

  • Standard dosing for alcohol use disorders ranges from 30-60 mg/day 3
  • High-dose baclofen (up to 270 mg/day) has been studied with individually titrated dosing 6
  • Mean dosage at onset of first adverse effect is approximately 83 mg/day 2
  • Doses above 180 mg are associated with severe toxicity and potential death in overdose situations 7
  • Persistent adverse effects occur in about 53% of patients 2

Monitoring and Management

  • Careful monitoring is required when initiating baclofen, particularly in patients with advanced liver disease 3
  • Approximately 7% of patients discontinue baclofen due to adverse effects, typically at doses below 90 mg/day 2
  • Alertness disorders and depression are the adverse effects most frequently leading to discontinuation 2
  • No antidote is available for baclofen toxicity; treatment is only symptomatic 7
  • Laboratory abnormalities may include increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar 1

Risk Assessment

  • Self-poisoning risk is higher in patients with alcohol use disorders due to frequent comorbid psychiatric conditions 7
  • Potential co-ingestants should be considered, especially CNS depressants 7
  • Baclofen withdrawal syndrome can be mistaken for alcohol withdrawal syndrome, as both present with confusion, agitation, seizures, and delirium 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Baclofen Abuse due to Its Hypomanic Effect in Patients with Alcohol Dependence and Comorbid Major Depressive Disorder.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2017

Research

High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.